NEW YORK (GenomeWeb) – Cellecta announced today that it has been awarded a Phase II SBIR grant from the National Institutes of Health to complete development of a genome-wide CRISPR/Cas9 screening platform that it aims to commercialize by late 2018.

CRISPR/Cas9 involves the use of an enzyme to cause double-strand DNA breaks that induce gene silencing. The process can be targeted to specific areas of the genome using so-called single guide RNAs (sgRNAs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.